What to expect with RYBREVANT FASPRO™–based or RYBREVANT®-based treatments
Get more information about the treatment, possible side effects, and how to prepare.
EGFR+, mutated epidermal growth factor receptor; NSCLC, non–small cell lung cancer.


RYBREVANT FASPRO™ + chemotherapy
and RYBREVANT® + chemotherapy
are 1st treatments for people with
EGFR+ NSCLC with exon 20 insertion mutations.
Actor portrayals.
What to expect with RYBREVANT FASPRO™–based or RYBREVANT®-based treatments
Get more information about the treatment, possible side effects, and how to prepare.
EGFR+, mutated epidermal growth factor receptor; NSCLC, non–small cell lung cancer.


Facing lung cancer comes with many challenges, but you're not alone.
There are many groups that can help support people living with lung cancer as well as their loved ones.

Once prescribed RYBREVANT FASPRO™ or RYBREVANT®, connect with a Care Navigator for your support needs.